These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 16856620

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
    Wong VW, Wong GL, Tsang SW, Hui AY, Chim AM, Yiu KK, Chan HY, Chan FK, Sung JJ, Chan HL.
    Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.
    Tsubota A, Arase Y, Suzuki F, Kobayashi M, Matsuda M, Sato J, Suzuki Y, Akuta N, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kumada H.
    J Med Virol; 2004 May; 73(1):7-12. PubMed ID: 15042641
    [Abstract] [Full Text] [Related]

  • 5. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.
    Manolakopoulos S, Bethanis S, Elefsiniotis J, Karatapanis S, Triantos C, Sourvinos G, Touloumi G, Economou M, Vlachogiannakos J, Spandidos D, Avgerinos A, Tzourmakliotis D.
    Aliment Pharmacol Ther; 2006 Mar 15; 23(6):787-95. PubMed ID: 16556181
    [Abstract] [Full Text] [Related]

  • 6. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy.
    Suzuki F, Tsubota A, Akuta N, Someya T, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H.
    J Gastroenterol; 2002 Mar 15; 37(11):922-7. PubMed ID: 12483247
    [Abstract] [Full Text] [Related]

  • 7. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
    Chan HL, Wang H, Niu J, Chim AM, Sung JJ.
    Antivir Ther; 2007 Mar 15; 12(3):345-53. PubMed ID: 17591024
    [Abstract] [Full Text] [Related]

  • 8. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN, Osiowy C, Giles E, Tomlinson G, Heathcote EJ.
    J Viral Hepat; 2005 Jul 15; 12(4):398-404. PubMed ID: 15985011
    [Abstract] [Full Text] [Related]

  • 9. Stopping lamivudine therapy after biochemical breakthrough may be a feasible option in selected HBeAg-positive patients.
    Jang JW, Choi JY, Bae SH, Yoon SK, Kim CW, Nam SW, Lee CD, Lee YS, Cha SB, Chung KW.
    J Med Virol; 2005 Nov 15; 77(3):367-73. PubMed ID: 16173025
    [Abstract] [Full Text] [Related]

  • 10. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
    Ozgenç F, Arikan C, Sertoz RY, Nart D, Aydogdu S, Yagci RV.
    Antivir Ther; 2004 Oct 15; 9(5):729-32. PubMed ID: 15535410
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B.
    Rizzetto M.
    J Med Virol; 2002 Apr 15; 66(4):435-51. PubMed ID: 11857520
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Response predictors and results of a long-term treatment with lamivudine in patients with chronic hepatitis B.
    Mihm U, Sarrazin C, Herrmann E, Teuber G, von Wagner M, Kronenberger B, Zeuzem S.
    Z Gastroenterol; 2003 Mar 15; 41(3):249-54. PubMed ID: 12664345
    [Abstract] [Full Text] [Related]

  • 14. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
    Viganò M, Colombo M, Aroldi A, Lunghi G, Manenti E, Ponticelli C, Lampertico P.
    Antivir Ther; 2005 Mar 15; 10(6):709-13. PubMed ID: 16218169
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Clinical outcome in cases of viral breakthrough during lamivudine therapy in chronic hepatitis B patients].
    Ahn SH, Chang YJ, Oh SN, Choi DW, Baek SJ, Jeong WS, Choi CW, Kim KO, Yim HJ, Jo NY, Bak JJ, Kim JS, Bak YT, Lee MS, Yeon JE, Byun KS, Lee CH.
    Taehan Kan Hakhoe Chi; 2002 Dec 15; 8(4):389-96. PubMed ID: 12506243
    [Abstract] [Full Text] [Related]

  • 19. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
    Yen YH, Lu SN, Chen CH, Wang JH, Wu CM, Hung CH, Tseng PL, Hu TH, Changchien CS, Lee CM.
    Liver Int; 2007 Dec 15; 27(10):1349-55. PubMed ID: 18036099
    [Abstract] [Full Text] [Related]

  • 20. Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.
    Kobayashi M, Suzuki F, Akuta N, Suzuki Y, Arase Y, Ikeda K, Hosaka T, Sezaki H, Kobayashi M, Iwasaki S, Sato J, Watahiki S, Miyakawa Y, Kumada H.
    J Med Virol; 2006 Oct 15; 78(10):1276-83. PubMed ID: 16927289
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.